Literature DB >> 3019665

Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.

C L Verweij, P J Diergaarde, M Hart, H Pannekoek.   

Abstract

Full-length human von Willebrand factor (vWF) cDNA was assembled from partial, overlapping vWF cDNAs. This cDNA construct includes a coding sequence of 8439 nucleotides which encode a single-chain precursor of 2813 amino-acid residues, representing a putative signal peptide, a prosequence and mature vWF of 22, 741 and 2050 amino acids, respectively. This represents the longest coding sequence determined to date. In-vitro expression of full-length vWF cDNA revealed the synthesis of a polypeptide with a mol. wt corresponding with that of the unglycosylated precursor. The precursor is a highly repetitive protein which consists of two duplicated (B, C), a triplicated (A), a quadruplicated (D) and a partly duplicated domain (D'), in the following order: H-D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-C1-C2-OH. Both the prosequence, composed of two D domains (D1, D2), and mature vWF harbor an arg-gly-asp ('R-G-D') sequence which has been implicated in cell-attachment functions. It is argued that the pro-sequence is equivalent to von Willebrand Antigen II (vW AgII).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019665      PMCID: PMC1167049          DOI: 10.1002/j.1460-2075.1986.tb04435.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  40 in total

1.  Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease.

Authors:  C S Jenkins; D R Phillips; K J Clemetson; D Meyer; M J Larrieu; E F Lüscher
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

2.  Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids.

Authors:  A J Berk; P A Sharp
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

3.  Dispersity of human factor VIII--Von Willebrand factor.

Authors:  J A van Mourik; P A Bolhuis
Journal:  Thromb Res       Date:  1978-07       Impact factor: 3.944

4.  von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.

Authors:  R R Montgomery; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

5.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium.

Authors:  K S Sakariassen; P A Bolhuis; J J Sixma
Journal:  Nature       Date:  1979-06-14       Impact factor: 49.962

8.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.

Authors:  R Nachman; R Levine; E A Jaffe
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

View more
  58 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

2.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

3.  A comprehensive list of cloned human DNA sequences.

Authors:  J Schmidtke; D N Cooper
Journal:  Nucleic Acids Res       Date:  1988       Impact factor: 16.971

4.  Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization.

Authors:  J N Wilcox; K M Smith; L T Williams; S M Schwartz; D Gordon
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

5.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

7.  Cloning and genomic characterization of LST1: a new gene in the human TNF region.

Authors:  I Holzinger; A de Baey; G Messer; G Kick; H Zwierzina; E H Weiss
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.

Authors:  Sandra L Haberichter; Elizabeth P Merricks; Scot A Fahs; Pamela A Christopherson; Timothy C Nichols; Robert R Montgomery
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

9.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

10.  The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.

Authors:  A Leyte; J Voorberg; H B Van Schijndel; B Duim; H Pannekoek; J A Van Mourik
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.